Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

To counteract these challenges, novel strategies aim to restore the cancer immunity cycle. One approach involves directly injecting unadjuvanted influenza vaccines or drug-loaded oncolytic viruses ...

To address these limitations of DC as immunotherapeutic agent, we have developed a polymeric nanocomplex incorporating (1) oncolytic adenovirus (oAd ... Furthermore, oAd/APP+DC treatment led superior ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

Around three-quarters of people with diabetes would prefer to swallow a pill daily than have regular injections ... short interfering RNA (siRNA) – a treatment which can silence certain genes ...

When giving gluteal injections, it is safest to use the upper ... his chances of recovery were small. The recommended treatment ranges from a conservative approach to immediate operative exposure ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedicine and Biotechnology, Shenzhen Institute ...